Lakefront Biotherapeutics NV Free Cash Flow (FCF) History (LKFT)

Lakefront Biotherapeutics NV reported −€271.2M in free cash flow for fiscal 2025, an increase of €65.6M from the previous fiscal year, with a free cash flow margin of −24.38%.

View full Lakefront Biotherapeutics NV company overview

Lakefront Biotherapeutics NV free cash flow by year

Lakefront Biotherapeutics NV annual free cash flow

Fiscal yearPeriod endedFree cash flowChangeGrowthFCF margin
20252025-12-31−€271.2M€65.6M−24.38%
20242024-12-31−€336.7M€87.9M−122.16%
20232023-12-31−€424.7M€103.3M−177.15%
20222022-12-31−€527.9M€30.1M−218.83%
20212021-12-31−€558.0M−€88.2M−238.08%
20202020-12-31−€469.9M−€3.66B−98.29%
20192019-12-31€3.19B€3.34B+381.63%
20182018-12-31−€152.9M−€516,000−54.85%
20172017-12-31−€152.3M−€387.3M−119.87%
20162016-12-31€234.9M€355.6M+181.40%
20152015-12-31−€120.7M−305.06%

Lakefront Biotherapeutics NV free cash flow growth trends

Over the last five reported fiscal years, free cash flow grew from −€469.9M to −€271.2M, a net increase of €198.7M.

About the metric

What free cash flow means

Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.

Calculation and source

How free cash flow is calculated

TickerStat calculates free cash flow as SEC-reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.

Review Lakefront Biotherapeutics NV filings at SEC.gov ↗